EcoR1, Oleg Nodelman disclose 9.0% stake in Fulcrum (NASDAQ: FULC)
Rhea-AI Filing Summary
Fulcrum Therapeutics reports large passive holdings by EcoR1 and affiliated parties. EcoR1 Capital, LLC and Oleg Nodelman each report beneficial ownership of 6,000,000 shares (listed as 9.0% of common stock), and EcoR1 Capital Fund Qualified, L.P. reports 5,614,199 shares (8.4%), with percentages calculated using 66,633,321 shares outstanding as of April 20, 2026. The filing states shared voting and dispositive power for the reported holdings and includes a joint-filing agreement; the reporting persons disclaim group status and certain beneficial ownership beyond pecuniary interests.
Positive
- None.
Negative
- None.
Insights
EcoR1 and its principal report single-digit stakes that could influence engagement rather than control.
The filing shows shared voting and dispositive power over 6,000,000 shares for EcoR1 and Mr. Nodelman, representing 9.0% of the class based on 66,633,321 shares outstanding as of April 20, 2026. This level typically permits active engagement but does not imply control.
Future filings may disclose any changes in voting arrangements or plans; cash-flow treatment and intent beyond the disclosed statement are not included in the excerpt.
Holdings are material at the holder level but below majority thresholds; they warrant monitoring for engagement activity.
The excerpt quantifies holdings—6,000,000 shares and 5,614,199 shares—and explicitly attributes shared power for voting and disposition. The filing includes a joint-filing agreement and a disclaimer against group status.
Watch for amendments or Schedule 13D conversions that would signal active campaign or control-seeking; timing and intent are not stated here.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficial Ownership regulatory
FAQ
What stake does EcoR1 report in Fulcrum Therapeutics (FULC)?
How much does Oleg Nodelman personally report owning in FULC?
What stake does EcoR1 Capital Fund Qualified, L.P. report in Fulcrum?
Do the reporting persons claim control of Fulcrum Therapeutics?
What voting and disposition powers are disclosed for these holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.